Author Archives: Press Release
BD Resolves Previously Disclosed SEC Investigation
BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
CancerVax Targets Hard to Treat Pancreatic Cancer
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®
Canary Speech Named to the 2024 CB Insights’ List of the 50 Most Innovative Digital Health Startups
Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized
Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
